Diagnosis of prostate cancer using differentially expressed genes in stroma

Cancer Research

Volumn 71, Issue 7, 2011, Pages 2476-2487

  Jia, Zhenyu ^a   Wang, Yipeng ^a,b   Sawyers, Anne ^a   Yao, Huazhen ^a,b   Rahmatpanah, Farahnaz ^a   Xia, O Qin ^a,b   Xu, Qiang ^c   Pio, Rebecca ^a   Turan, Tolga ^a   Koziol, James A ^d   Goodison, Steve ^e   Carpenter, Philip ^a   Wang Rodriguez, Jessica ^f,g   Simoneau, Anne ^a   Meyskens, Frank ^h   Sutton, Manuel ^a   Lernhardt, Waldemar ⁱ   Beach, Thomas ^j   Monforte, Joseph ^c   McClelland, Michael ^a,b   Mercola, Dan ^a   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Vaccine Research Institute of San Diego   (United States)

^c Althea Technologies   (United States)

^d SCRIPPS RESEARCH INSTITUTE   (United States)

^e M D ANDERSON CANCER CENTER ORLANDO   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ Proveri Inc   (United States)

^j SUN HEALTH RESEARCH INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AGE; ARTICLE; CLASSIFIER; CONTROLLED STUDY; DIAGNOSTIC VALUE; GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; STROMA; TUMOR MICROENVIRONMENT;

AGED; AGED, 80 AND OVER; BIOPSY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; RNA, NEOPLASM; STROMAL CELLS;

EID: 79953309070     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-2585     Document Type: Article

References (36)

1. Marks LS, Bostwick DG. Prostate cancer specificity of PCA3 gene testing: examples from clinical practice. Rev Urol 2008;10:175-81.
2. O'Dowd G J, Miller MC, Orozco R, Veltri RW. Analysis of repeated biopsy results within 1 year after a noncancer diagnosis. Urology 2000;55:553-9.
3. Che M, Sakr W, Grignon D. Pathologic features the urologist should expect on a prostate biopsy. Urol Oncol 2003;21:153-61. (Pubitemid 41123442)
4. Pepe P, Aragona F. Saturation prostate needle biopsy and prostate cancer detection at initial and repeat evaluation. Urology 2007;70:1131-5. (Pubitemid 350297372)
5. Andriole GL, Bullock TL, Belani JS, Traxel E, Yan Y, Bostwick DG, et al. Is there a better way to biopsy the prostate? Prospects for a novel transrectal systematic biopsy approach. Urology 2007;70 Suppl:22-6.
6. Mian BM, Naya Y, Okihara K, Vakar-Lopez F, Troncoso P, Babaian RJ. Predictors of cancer in repeat extended multisite prostate biopsy in men with previous negative extended multisite biopsy. Urology 2002;60:836-40. (Pubitemid 35300350)
7. Leite KR, Camara-Lopes LH, Cury J, Dall'oglio MF, Sanudo A, Srougi M. Prostate cancer detection at rebiopsy after an initial benign diagnosis: results using sextant extended prostate biopsy. Clinics 2008;63:339-42.
8. Amin MM, Jeyaganth S, Fahmy N, Bégin L, Aronson S, Jacobson S, et al. Subsequent prostate cancer detection in patients with prostatic intraepithelial neoplasia or atypical small acinar proliferation. Can Urol Assoc J 2007;1:245-9.
9. Cunha GR, Hayward SW, Wang YZ. Role of stroma in carcinogenesis of the prostate. Differentiation 2002;70:473-85. (Pubitemid 36194313)
10. Cunha GR, Hayward SW, Wang YZ, Ricke WA. Role of the stromal microenvironment in carcinogenesis of the prostate. Int J Cancer 2003;107:1-10. (Pubitemid 37100079)
11. Ernst T, Hergenhahn M, Kenzelmann M, Cohen CD, Bonrouhi M, Weninger A, et al. Decrease and gain of gene expression are equally discriminatory markers for prostate carcinoma: a gene expression analysis on total and microdissected prostate tissue. Am J Pathol 2002;160:2169-80. (Pubitemid 34663408)
12. Tuxhorn JA, Ayala GE, Smith MJ, Smith VC, Dang TD, Rowley DR. Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. Clin Cancer Res 2002;8:2912-23. (Pubitemid 35025739)
13. Chandran UR, Dhir R, Ma C, Michalopoulos G, Becich M, Gilbertson J. Differences in gene expression in prostate cancer, normal appearing prostate tissue adjacent to cancer and prostate tissue from cancer free organ donors. BMC Cancer 2005;5:45.
14. Yang SZ, Dong JH, Li K, Zhang Y, Zhu J. Detection of AFPmRNA and melanoma antigen gene-1mRNA as markers of disseminated hepatocellular carcinoma cells in blood. Hepatobiliary Pancreat Dis Int 2005;4:227-33. (Pubitemid 40790170)
15. Verona EV, Elkahloun AG, Yang J, Bandyopadhyay A, Yeh IT, Sun LZ. Transforming growth factor-beta signaling in prostate stromal cells supports prostate carcinoma growth by up-regulating stromal genes related to tissue remodeling. Cancer Res 2007;67:5737-46. (Pubitemid 46985006)
16. Richardson AM, Woodson K, Wang Y, Rodriguez-Canales J, Erickson HS, Tangrea MA, et al. Global expression analysis of prostate cancer-associated stroma and epithelia. Diagn Mol Pathol 2007;16:189-97. (Pubitemid 350196975)
17. Dakhova O, Ozen M, Creighton CJ, Li R, Ayala G, Rowley D, et al. Global gene expression analysis of reactive stroma in prostate cancer. Clin Cancer Res 2009;15:3979-89.
18. Van Der Heul-Nieuwenhuijsen L, Dits N, Van Ijcken W, de Lange D, Jenster G. The FOXF2 pathway in the human prostate stroma. Prostate 2009;69:1538-47.
19. Yang F, Tuxhorn JA, Ressler SJ, McAlhany SJ, Dang TD, Rowley DR. Stromal expression of connective tissue growth factor promotes angiogenesis and prostate cancer tumorigenesis. Cancer Res 2005;65:8887-95. (Pubitemid 41377378)
20. Stuart RO, Wachsman William, Berry Charles C, Arden Karen, Goodison Steven, Klacansky Igor, , et al. In silico dissection of cell-type associated patterns of gene expression in prostate cancer. Proc Natl Acad Sci U S A 2004;101:615-20.
21. Simoneau AR, Gerner EW, Nagle R, Ziogas A, Fujikawa-Brooks S, Yerushalmi H, et al. The effect of difluoromethylornithine on decreasing prostate size and polyamines in men: results of a year-long phase IIb randomized placebo-controlled chemoprevention trial. Cancer Epidemiol Biomarkers Prev 2008;17:292-9. (Pubitemid 351272778)
22. Stephenson AJ, Smith A, Kattan MW, Satagopan J, Reuter VE, Scardino PT, et al. Integration of gene expression profiling and clinical variables to predict prostate carcinoma recurrence after radical prostatectomy. Cancer 2005;104:290-8. (Pubitemid 40993255)
23. Sun Y, Goodison S. Optimizing molecular signatures for predicting prostate cancer recurrence. Prostate 2009;69:1119-27.
24. Liu P, Ramachandran S, Ali Seyed M, Scharer CD, Laycock N, Dalton WB,et al. Sex-determining regionYbox 4 is a transformingoncogene in human prostate cancer cells. Cancer Res 2006;66:4011-9. Available from: http://www.ebi.ac.uk/ arrayexpress/browse.html?keywords=E-TABM-26.
25. Dalgaard P. Statistics and Computing: Introductory Statistics with R. New York: Springer-Verlag Inc.; 2002. p. 260.
26. SPECS Web site. Available from: http://www.pathology.uci.edu/faculty/ mercola/UCISPECSHome.html [cited 2007 May 21].
27. Guo Y, Hastie T, Tibshirani R. Regularized linear discriminant analysis and its application in microarrays. Biostatistics 2007;8:86-100. (Pubitemid 44906104)
28. Tibshirani R, Hastie T, Narasimhan B, Chu G. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci U S A 2002;99:6567-72. (Pubitemid 34526173)
29. Wang Y, Xiao-Qin Xia, Zhenyu Jia, Anne Sawyers, Huazhen Yao, Jessica Wang-Rodriquez, et al. In silico estimates of tissue components in surgical samples based on expression profiling data using. Cancer Res In press. Available from: http://webarraydborg/webarray/indexhtml.
30. Tuxhorn JA, Ayala GE, Rowley DR. Reactive stroma in prostate cancer progression. J Urol 2001;166:2472-83. (Pubitemid 33065339)
31. Rowley DR. What might a stromal response mean to prostate cancer progression? Cancer Metastasis Rev 1998;17:411-9.
32. Yanagisawa N, Li R, Rowley D, Liu H, Kadmon D, Miles BJ, et al. Stromogenic prostatic carcinoma pattern (carcinomas with reactive stromal grade 3) in needle biopsies predicts biochemical recurrence-free survival in patients after radical prostatectomy. Hum Pathol 2007;38:1611-20. (Pubitemid 47589095)
33. Shariat SF, Scardino PT, Lilja H. Screening for prostate cancer: an update. Can J Urol 2008;15:4363-74.
34. Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 2003;4:P3.
35. Tuxhorn JA, McAlhany SJ, Yang F, Dang TD, Rowley DR. Inhibition of transforming growth factor-beta activity decreases angiogenesis in a human prostate cancer-reactive stroma xenograft model. Cancer Res 2002;62:6021-5. (Pubitemid 35244446)
36. Zhang Q, Helfand BT, Jang TL, Zhu LJ, Chen L, Yang XJ, et al. Nuclear factor-kappaB-mediated transforming growth factor-beta-induced expression of vimentin is an independent predictor of biochemical recurrence after radical prostatectomy. Clin Cancer Res 2009;15:3557-67.